← Back to Search

Interleukin-1 inhibitor

Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss

Phase < 1
Waitlist Available
Led By Stanley B Cohen, MD
Research Sponsored by Stanley Cohen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing rilonacept, a drug that reduces inflammation, on patients with progressive hearing loss in both ears. The goal is to see if reducing inflammation can help improve or stabilize their hearing.

Eligible Conditions
  • Autoimmune Hearing Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Improvement in hearing in comparison to baseline values
Secondary study objectives
Pt reported evaluation of auditory acuity
Quality of Life assessment
Tinnitus evaluation
+1 more

Side effects data

From 2014 Phase 4 trial • 42 Patients • NCT01663103
14%
upper respiratory infection
5%
Injection site reaction
5%
Neck abscess/pyomyositis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rilonacept
Placebo

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RilonaceptExperimental Treatment1 Intervention
A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rilonacept
FDA approved

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsIndustry Sponsor
671 Previous Clinical Trials
385,833 Total Patients Enrolled
Stanley CohenLead Sponsor
Stanley B Cohen, MDPrincipal InvestigatorMetroplex Clinical Research Center
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top